Immucell (ICCC) Growth Rates Comparisons to In Vitro & In Vivo Diagnostic Substances Industry, Sector, Market. Sales, Income, EPS
CSIMarket Company Name, Ticker, Competitors, else..
 
Immucell Corporation  (NASDAQ: ICCC)
 

Immucell Growth Comparisons

Select each growth Category to receive further Information




Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ICCC Revenue Growth Rate Comparisons Company Industry Sector S&P 500
Y / Y Revenue Growth (Q2 MRQ) 11.5 % 2.79 % 8.91 % 10.9 %
Q / Q Revenue Growth (Q2 MRQ) -25.59 % -4.32 % -3.28 % 8.32 %
Y / Y Revenue Growth (for 12 months ending Q2 TTM) 1.01 % 4.02 % 7.98 % %
Sequential Revenue Growth (for 12 months ending Q2 TTM) 2.55 % 0.68 % 2.03 % 2.61 %
Revenue 5 Year Average Growth 12.34 % 11.98 % 8.65 % 10.59 %


ICCC's Growth Comparisons in II. Quarter 2026




Immucell improved it's Revenue by 11.5% year on year in the second quarter 2026, and outpaced the 2.79% growth in the In Vitro & In Vivo Diagnostic Substances industry, and 8.91% growth in the Healthcare sector. Despite modest Sales rises in the Healthcare sector and in the In Vitro & In Vivo Diagnostic Substances industry, Immucell Corporation reported above average market Sales growth.

Top-line fell by -25.59% from the first quarter results. Comparing the annual growth, sales of 12.34% on average in last five years, to the S & P 500's, including only Businesses with the second quarter 2026 financial results, average yearly sales growth is 10.59%. Immucell grew faster than the market.

ICCC Growth Rates by Company's Segments

Segment Name
Y / Y
Sequential
US
-
-
Non Us
-
-
Corporate Segment Scours
-
-
Total
-
-25.59 %


Growth Rates of ICCC's Income in the second quarter 2026


ICCC Operating Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Operating Income Change (Q2 MRQ) 239.72 % -20.76 % 4.62 % 97.6 %
Sequential Operating Income Change (Q2 MRQ) -1.75 % 83.24 % 0.89 % 48.13 %
Y / Y Operating Income Growth (Q2 TTM) 123.01 % - 30.73 % 40.67 %
Sequential Operating Income Growth (Q2 TTM) 54.59 % - 4.82 % 20.86 %
Operating Income 5 Year Avg. Change - - 10.39 % 18.76 %


Income from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Income from Cont. Ops. Change (Q2 MRQ) 265.56 % -39.26 % -25.98 % 90.69 %
Sequential Income from Cont. Ops. Change (Q2 MRQ) -5.51 % - -66.16 % 27.07 %
Y / Y Income from Cont. Ops. Change (Q2 TTM) -55.31 % - 2.68 % 57.33 %
Sequential Income from Cont. Ops. Change (Q2 TTM) - - -5.02 % 18.65 %
Income from Cont. Ops. 5 Year Avg. Change - - 0.17 % -28.52 %

ICCC Net Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Net Income Growth (Q2 MRQ) 265.56 % -39.26 % -26.26 % 90.69 %
Q / Q Net Income Growth (Q2 MRQ) -5.51 % - -0.77 % 27.07 %
Y / Y Net Income Change (Q2 TTM) -55.31 % - 15.51 % 57.33 %
Sequential Net Income Change (Q2 TTM) - - -6.72 % 18.65 %
Net Income 5 Year Avg. Growth - - 9.21 % 22.96 %

ICCC's EPS Growth Rates


EPS from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS from Cont. Ops. Change (Q2 MRQ) 233.33 % -42.65 % -25.98 % 90.69 %
Sequential EPS from Cont. Ops. Change (Q2 MRQ) -4.76 % - -66.16 % 27.07 %
Y / Y EPS from Cont. Ops. Change (Q2 TTM) -62.67 % - - -
Sequential EPS from Cont. Ops. Change (Q2 TTM) - - - 4.88 %
EPS from Cont. Ops. 5 Year Avg. Growth - - 0.17 % -28.52 %



ICCC EPS Net Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS Net Growth (Q2 MRQ) 233.33 % -42.65 % -26.26 % -28.52 %
Q / Q EPS Net Growth (Q2 MRQ) -4.76 % - -0.77 % 27.07 %
Y / Y EPS Net Change (for 12 months ending Q2 TTM) - - - 7.62 %
Sequential EPS Net Change (for 12 months ending Q2 TTM) - - - 4.93 %
EPS Net 5 Year Avg. Change - - 9.21 % 22.96 %



Despite the -42.65% decline in In Vitro & In Vivo Diagnostic Substances industry, Immucell showed impressive surge in EPS in the second quarter by 233.33% from the same quarter a year ago, to $0.20, Healthcare sector dropped -26.26%. Despite modest earnings per share in the In Vitro & In Vivo Diagnostic Substances industry and ind the Healthcare sector, Immucell Corporation reported above average market earnings per share growth.

the bottom-line fell by -4.76% from the first quarter. Average annual income per share growth for Immucell is 12.34%, while S & P 500's average yearly income per share increase is 22.96%, including only Businesses with the second quarter 2026 earnings.

ICCC Cash Flow Growth Rates


Free Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Free Cash Flow Change (Q2 MRQ) 58 % 36.53 % 48.49 % 48.62 %
Sequential Free Cash Flow Change (Q2 MRQ) -32.71 % -78.85 % -46.96 % 34.18 %
Y / Y Free Cash Flow Change (Q2 TTM) 138.92 % 17.22 % 18.61 % 60.27 %
Sequential Free Cash Flow Change (Q2 TTM) 24.85 % -0.48 % 5.39 % 15.75 %
Free Cash Flow 5 Year Avg. Change - -14.19 % 0.92 % 8.28 %

Net Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Net Cash Flow Change (Q2 MRQ) - - - 339.02 %
Sequential Net Cash Flow Change (Q2 MRQ) - - - 216.68 %
Y / Y Net Cash Flow Change (Q2 TTM) -82.58 % - - 209.43 %
Sequential Net Cash Flow Change (Q2 TTM) - - - 152.64 %
Net Cash Flow 5 Year Avg. Change -40.59 % - 6.46 % 1.06 %

Capital Expenditures Company Industry Sector S&P 500
Y / Y Capital Expenditures Change (Q2 MRQ) 373 % -33.37 % 8.23 % 120.03 %
Sequential Capital Expenditures Change (Q2 MRQ) 314.09 % -12.68 % -22.09 % 36.87 %
Y / Y Capital Expenditures Change (Q2 TTM) 118.17 % -27.45 % 7.87 % 109.38 %
Sequential Capital Expenditures Change (Q2 TTM) 52.68 % -9.85 % 1.6 % 23.05 %
Capital Expenditures 5 Year Avg. Change -21.03 % 16.55 % 9.12 % 14.73 %

Note
To view Detail Information & Trends click on Individual Category.
To see Industry, Sector or S&P 500 Performance, click on each Category respectivly, on the top of the Table.

For explanation of terms visit: Glossary
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Y/Y Annual




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.